CLAIMS

1. Use of a Compound (I) in the manufacture of a medicament for the treatment of a disease in the central nervous system, characterized in that Compound (I) is to be administered semiweekly or weekly in an instant release formulation (IR-formulation), an extended, controlled or a delayed release formulation for oral administration in a dose corresponding to between 20 mg/week and 50 mg/week, calculated as the free base of Compound (I).

2. The use according to claim 1, wherein Compound (I) is to be administered weekly in a dose, calculated as the free of base Compound (I), between 20 mg/dose and 50 mg/dose.

3. The use according to claim 1 or 2, wherein Compound (I) is to be administered weekly in a dose, calculated as the free base of Compound (I), between about 30 mg/dose and about 45 mg/dose.

4. The use according to claim 1, 2 or 3, wherein Compound (I) is to be administered weekly in a dose, calculated as the free base of Compound (I), of about 30 mg/dose.

5. The use according to claim 1, 2 or 3, wherein Compound (I) is to be administered weekly in a dose, calculated as the free base of Compound (I), of about 45 mg/dose.

6. The use according to Claim 1 wherein the disease is selected from the group of diseases consisting of psychosis, in particular schizophrenia or other diseases involving psychotic symptoms, such as, Schizophrenia, Schizophreniform Disorder, Schizoaffective Disorder, Delusional Disorder, Brief Psychotic Disorder, Shared Psychotic Disorder as well other psychotic disorders or diseases that present with psychotic symptoms, e.g. bipolar disorder, such as mania in bipolar disorder, and for treatment of psychosis in Parkinson's Disease.

7. Use according to claim 1 wherein the medicament further comprises a compound selected from the group consisting of sertindole, olanzapine, risperidone, quetiapine, aripiprazole, haloperidol, clozapine, ziprasidone and osanetant for use in the treatment of psychosis, in particular schizophrenia or other diseases involving psychotic symptoms, such as, Schizophreniform Disorder, Schizoaffective Disorder, Delusional Disorder, Brief Psychotic Disorder, Shared Psychotic Disorder as well other psychotic disorders or diseases that present with psychotic symptoms, e.g. bipolar disorder, such as mania in bipolar disorder, and for treatment of psychosis in Parkinson's Disease, wherein Compound (I) is to be administered semiweekly or weekly in an instant release formulation (IR-formulation), an extended, controlled or a delayed release formulation for oral administration in a dose corresponding to between 20 mg/week and 50 mg/week calculated as the free base of Compound (I).

8. A pharmaceutical composition comprising Compound (I) or a salt of Compound (I) and one or more pharmaceutically acceptable carriers, diluents and excipients for use in the treatment of a disease in the central nervous system, in particular psychosis, such as schizophrenia, characterized in that the pharmaceutical composition comprising Compound (I) is administered semiweekly or weekly in an instant release formulation (IR-formulation), an extended, controlled or a delayed release formulation for oral administration.

9. The pharmaceutical composition of claim 8, further comprising one or more neuroleptic agents selected from sertindole, olanzapine, risperidone, quetiapine, aripiprazole, haloperidol, clozapine, ziprasidone and osanetant.

CLAIMS

1. Use of a Compound (I) in the manufacture of a medicament for the treatment of a disease in the central nervous system, characterized in that Compound (I) is to be administered semiweekly, weekly or biweekly in a dose corresponding to between 20 mg/week and 50 mg/week calculated as the free base of Compound (I)

2. The use according to claim 1, wherein Compound (I) is to be administered weekly in a dose, calculated as the free of base Compound (I), between 20 mg/dose and 50 mg/dose.

3. The use according to claim 1 or 2 , wherein Compound (I) is to be administered weekly in a dose, calculated as the free base of Compound (I), between about 30 mg/dose and about 45 mg/dose.

4. The use according to claim 1, 2 or 3, wherein Compound (I) is to be administered weekly in a dose, calculated as the free base of Compound (I), of about 30 mg/dose.

5. The use according to claim 1, 2 or 3, wherein Compound (I) is to be administered weekly in a dose, calculated as the free base of Compound (I), of about 45 mg/dose.

6. The use according to Claim 1 wherein the disease is selected from the group of diseases consisting of psychosis, in particular schizophrenia or other diseases involving psychotic symptoms, such as, Schizophrenia, Schizo-phreniform Disorder, Schizoaffective Disorder, Delusional Disorder, Brief Psychotic Disorder, Shared Psychotic Disorder as well other psychotic disorders or diseases that present with psychotic symptoms, e.g. bipolar disorder, such as mania in bipolar disorder, and for treatment of psychosis in Parkinson's Disease.

7. Use of Compound (I) for the manufacture of a medicament for the treatment of psychosis, in particular schizophrenia or other diseases involving psychotic symptoms, such as, Schizophreniform Disorder, Schizoaffective Disorder, Delusional Disor-der, Brief Psychotic Disorder, Shared Psychotic Disorder as well other psychotic dis-orders or diseases that present with psychotic symptoms, e.g. bipolar disorder, such

as mania in bipolar disorder, and for treatment of psychosis in Parkinson's Disease, wherein Compound (I) is administered semiweekly, weekly or biweekly in a dose corresponding to between 20 mg/week and 50 mg/week calculated as the free base of Compound (I).

8. Use according to claim 7 wherein the medicament further comprises a compound selected from the group consisting of sertindole, olanzapine, risperidone, quetiapine, aripiprazole, haloperidol, clozapine, ziprasidone and osanetant for the treatment of psychosis, in particular schizophrenia or other diseases involving psychotic symptoms, e.g., Schizophreniform Disorder, Schizoaffective Disorder, Delusional Disorder, Brief Psychotic Disorder, Shared Psychotic Disorder as well other psychotic disorders or diseases that present with psychotic symptoms, e.g. bipolar disorder, such as mania in bipolar disorder, and for treatment of psychosis in Parkinson's Disease, wherein Compound (I) is to be administered semiweekly, weekly or biweekly in a dose corresponding to between 20 mg/week and 50 mg/week calculated as the free base of Compound (I).

9. A pharmaceutical composition comprising Compound (I) or a salt of Compound (I) and one or more pharmaceutically acceptable carriers, diluents and excipients for the treatment of a disease in the central nervous system, in particular psychosis, such as schizophrenia, characterized in that the pharmaceutical composition comprising Compound (I) is administered semiweekly, weekly or biweekly.

10. The pharmaceutical composition of claim 9 further comprising one or more neuroleptic agents selected from sertindole, olanzapine, risperidone, quetiapine, aripiprazole, haloperidol, clozapine, ziprasidone and osanetant.